19 June 2017 - Horizon Pharma today announced that Health Canada has issued a notice of compliance for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children 2 years of age and older.

Procysbi is the only cystine-depleting agent approved in Canada for the treatment of nephropathic cystinosis. It is a delayed-release form of cysteamine bitartrate that works by continuously reducing the toxic concentration of cystine in the cells to limit or prevent the damage too much cystine can cause to cells, tissue and organs.

Read Horizon Pharma press release